Three things to know:
1. The researchers retrospectively analyzed 6,130 patients registered in the PearlDiver national database through Humana Insurance from 2007 to 2016. All ACDF patients with anterior plating who were active in the database for at least one year were included in the study.
2. The allograft group included 4,063 patients; the cage group included 2,067 patients.
3. Overall nonunion rates were significantly higher in the cage group — 5.32 percent — than in allograft group — 1.97 percent.
More articles on biologics:
SpinalCyte receives new regenerative medicine patents: 5 insights
New bone grafting policy includes Cerapedics’ peptide enhanced bone graft — 3 insights
Aesculap Biologics reaches halfway mark in clinical trial for knee articular cartilage defects: 5 insights
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
